Know Cancer

or
forgot password


Phase 3
18 Years
70 Years
Open (Enrolling)
Both
Leukemia, Myeloid, Philadelphia-Positive

Thank you

Trial Information


Inclusion Criteria:



- Ph+ CML patients in complete cytogenetic response (CCR) after more than 1 year of
imatinib therapy.

Exclusion Criteria:

- Patients in imatinib study

- Patients with a history of intolerability to interferon.

- Patients with less than CCR or less than one year of imatinib therapy.

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Izhar Hardan, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Sheba Medical Center

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

SHEBA-06-4015-IH-CTIL

NCT ID:

NCT00297570

Start Date:

February 2006

Completion Date:

Related Keywords:

  • Leukemia, Myeloid, Philadelphia-Positive
  • CML
  • Imatinib
  • Pegylated Interferon
  • Philadelphia Positive CML
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Name

Location